BLAINJECTIONSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STIMUFEND (pegfilgrastim-fpgk) is a long-acting granulocyte colony-stimulating factor (G-CSF) cytokine approved by the FDA in September 2022. It is indicated to reduce the incidence of infection, as manifested by febrile neutropenia, in patients receiving myelosuppressive anti-cancer drugs. The drug works by stimulating the proliferation and differentiation of hematopoietic progenitor cells into mature neutrophils, thereby mitigating chemotherapy-induced neutropenia.
Peak
Product is at peak commercial maturity with moderate competitive pressure (30); team expansion likely focused on market defense and penetration rather than launch activities.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
STIMUFEND is a peak-stage, mature-market product in a highly competitive biosimilar-sensitive category. Career growth on this product emphasizes commercial acumen, physician relationship management, payer negotiation, and supply chain execution rather than clinical or scientific innovation. This is ideal for professionals seeking to build competitive positioning and market defense expertise in a challenging, well-established therapeutic space.
Brand Manager
Worked on STIMUFEND at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.